Anticoncepción Oral en Perspectiva, Bibliografía

97 Risch HA, Marrett LD, Jain M, et al. Differences in risk factors for epithelial ovarian cancer by histologic type: Results of a case control study. Am J Epidemiol. 1996; 144: 363 372.
98 Vessey MP, Metcalfe A, Wells C, et al. Ovarian neoplasm, functional ovarian cysts and oral contraceptives Br Med J. 1987; 294: 1518 -1520.
99 Cancer and Steroid Hormone Study. Combination oral contraceptive use and the risk of endometrial cancer. J. Am. Med. Assoc. 1987; 257 (6): 796 800.
100 Schlesselman JJ. Oral contraceptives and neoplasia of the uterine corpus. Contraception. 1991; 43: 557- 559.
101 Schelesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner´s guide to metaanalysis. Hum Reprod. 1997; 12: 1851 1863.
102 Meirik O. La píldora y el cáncer de mama: Nueva información. Boletín Médico de la IPPF. 1996; 30 (6): 1 3.
103 Senanayake P, Kramer DG. Contraception and the etiology of pelvic inflammatory disease: New perspectives. Am J Obstet Gynecol. 1980; 138: 852 – 857.
104 Washington AE, Gove S, Schachter J, et al. Oral contraceptive, Chlamydea Trachomatis infection and pelvic inflammatory diseases: A word of caution about protection. JAMA. 1985; 253: 2246 – 2251.
105 Wolner-Hanssen P, Echembach DA, Paavonen J, et al. Decreased risk of symptomatic Chlamydial pelvic inflammatory disease associated with oral contraceptives. JAMA. 1990; 263: 54 – 63.
106 Harlap S. Benefits and risks of birth control in U.S. Women. Int J fertile. 1992; 37 (suppl 3): 148 156.
107 Mol BWJ, Ankum WM, Bossuyt PMN, et al. Contraception and the risk of ectopic pregnancy. A meta-analysis. Contraception. 1995; 52: 337-341.
108 Milman N, Clausen J, Byg KE. Iron status in 268 Danish women aged 18 30 years: influence of menstruation, contraceptive methods, and iron supplementation. Ann Hematol. 1998. 77 (1-2): 13 19.
109 Weng LJ, XU D, Zheng HZ, el al. Clinical experience with triphasic oral contraceptive (Triquilar) in 527 women in China. Contraception. 1991; 43: 263 271.
110 Spector TD, Hochberg MC. The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis. Rheumatoid arthritis. J. Chronic Dis. 1986; 10: 841 – 849.
111 Polatti F, Perotti F, Filippa N, et al. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception. 1995; 51: 221 224.
112 MacDougall J, Davies MC, Overton CE, et al. Bone density in a population of long term oral contraceptive pill users does not differ from that in menstruating women. Br J Fam Plann. 1999; 25(3): 96 – 100.
113 Cromer BA. Effects of hormonal contraceptives on bone mineral density. Drug Sa. 1999; 20(3): 213 – 222.
114 Kuohung W, Borgatta L, Stubblefield P. Low dose oral contraceptive and bone mineral density: an evidence based analysis. Contraception. 2000; 61: 77 82.
115 Borenstein J, Yu H, Wade S, et al. Effects of an oral contraceptive containing ethinyil Estradiol and drospirenone on premenstrual symptomatology and health related quality of life. J Reprod Med. 2003; 48(2): 79 85.
116 Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mgs or Levonorgestrel 150 ug on premenstrual symptoms. Contraception. 2005; 71 (1): 1 7.
117 Friedman AJ, Thomas PP. Does low – dose combination oral contraceptive use affect uterine size or menstrual flow in pre menopausal women with leiomyomas? Obstet Gynecol. 1995; 85: 631 – 835.
118 Ross RK, Pike MC, Vessey MP, et al. Risk factors for uterine fibroids reduced risk associated with oral contraceptives. Br Med J. 1986; 293: 359 362.
119 Chiaffarino F, Parazzini F, La Vechia C, et al. Use of oral contraceptives and uterine fibroids: Results from a case control study. Br J Obstet Gynaecol. 1981; 139: 277 280.
120 Del Marmol V, Teichmann A, Gertsen K. The role of combined oral contraceptives in the management of acne and seborrhea. Eur J Contracept Reprod Health Care. 2004; 9(2): 107- 124.
121 Rabe T, Kowald A, Ortmann J. Inhibition of skin 5 alpha reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol. 2000; 14(4): 223 – 230.
122 Comporato MR, Yabur JA, Bajares M. Contraceptivee efficacy and acceptability of a monophasic oral contraceptive containing 30 micrograms ethinyl Estradiol and 150 microg Desogestrel in Latin American women. Adv. Contraception. 1998; 14(1): 15 – 26.
123 Koulianos Gt. Treatment of acne with oral contraceptives. Criteria for pill selection. Cutis. 2000; 66(4): 281 – 286.
124 Escobar-Morreale HF, Lasuncion MA, Sancho J. Treatment of hirsutism with ethinyl Estradiol Desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity. Fertil Steril. 2000, 74(4): 816 – 819.
125 Fernandez E, La Vecchia C. Franceschi S, et al. Oral contraceptive use and risk of colorectal cancer. Epidemiology. 1988. 9: 295 300.
126 Martinez ME, Grodstein F, Giovannucci E, et al. A prospective Study of reproductive factor, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 1997. 6: 1 5.
127 Lobo R, Skinner JB, Lippman JS. Plasma lipids and Desogestrel and Ethinyl – Estradiol a meta-analysis. Fertil Steril. 1996; 65: 1100 -1109.
128 Burkman RT, Kafrissen ME, Olson W. Lipid and carbohydrate effects of a new Triphasic oral contraceptive containing Norgestimate. Acta Obstet Gynecol Scand. 1992; 71: 156 (suppl): 5S 8S.
129 Chapdelaine A, Desmarais JL, Derman RJ. Clinical evidence of the minimal androgenic activity of Norgestimate. Int J Fertil. 1989; 34: 347 – 352.
130 Patsch W, Brown SA, Gotto AM Jr, et al. The effect of triphasic oral contraceptives on plasma lipids and lipoproteins. Am J Obstet Gynecol. 1989; 161: 1396 – 1401.
131 Brill K, Then A, et al. Investigation of the influence of two low dose monophasic oral contraceptives containing 20 ug Ethinyl Estradiol / 75 ug Gestodene, and 30 ug ethinyl Estradiol / 75 ug Gestodene, on lipid metabolism in an open randomized trial. Contraception. 1996;
54: 291 – 297.
132 Gaspard U, Endrikat J, Desager JP, et al. A Randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception. 2004; 69: 271 278.
133 Petersen KR, Skouby SO, Vedel P, et al. Hormonal contraception in women with IDDM. Influence in glycometabolic control and lipoprotein metabolism. Diabetes Care. 1995; 18 (6): 800 – 806.
134 Kjos SL, Peters RK, Xiang A, et al. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestacional diabetes mellitus. JAMA. 1998; 280(6): 533 – 538.
135 Balogh A, Kauf E, Vollanth R, et al. Effects of two oral contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth hormone. Contraception. 2000; 62(5): 259 269.
136 Weinges KF, Wenzel E, Hellstern P, et al. The effects of two phasic oral contraceptives on hemostasis and platelet function. Adv. In contraception. 1995; 11: 227-237.
137 Lewis MA, MacRae KD, Kuhl-Habichi D. Et al. The differential risks of oral contraceptives the impact of full exposure history. Hum Reprod. 1999; 14(6): 1493 – 1499.
138 Winkler UH. Effects of progestins on cardiovascular diseases: the haemostatic system. Hum Reprod update. 1999; 5(3): 200 – 204.
139 Fruzzetti F. Hemostatic effects of smoking and oral contraceptive use. Am J Obstet Gynecol. 1999; 180 (6 pt2): 369S – 374S.
140 Word Health Organization Collaborative Study of cardiovascular disease and steroid hormone contraception. Venous Thromboembolic disease and combined oral contraceptives: resultsof international multicenter case control study. Lancet. 1995; 346:1575-1581.
141 Word Health Organization Collaborative Study of cardiovascular disease and steroid hormone contraception. Effects of different progestogens on low estrogen oral contraceptives on venous Thromboembolic disease. Lancet. 1995; 346:1582 1588.
142 Jick H, Kaye JA. Vasilakis-Scaramozza C, et al. Risk of venous thromboembolism among users of third generation oral contraceptive compared with users of oral contraceptives with Levonorgestrel before and after 1195: cohort and case-control analysis. BMJ. 2000; 321(7270): 1190 – 1195.
143 Suissa S, Spitzer WO, Rainville B, et al. Recurrent use of newer oral contraceptives and risk of venous thromboembolism. Hum Reprod. 2000; 15(4):817-821.
144 Middeldorp S, Meijers JC, Bouma BN, et al. Effects on coagulation of Levonorgestrel and Desogestrel containing low dose oral contraceptives: a cross-over study. Thromb Haemost. 2000; 84(1): 4- 8.
145 Tans G, Curvers J, Middeldorp S, et al. A Randomized cross over study on the effects of Levonorgestrel and Desogestrel containing oral contraceptives on the anticoagulation pathways. Thromb Haemost. 2000; 84(1): 15- 21.
146 Carter CJ. Oral contraceptives and thrombosis. Curr Opin Pulm Med. 2000: 6(4): 296 300.
147 Spannalgl M, Heinemann LA, Schramm W. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism? Eur J Contracept Reprod Health Care. 2000; 5(2): 105 – 112.
148 Zeitourt K. Carr BR. Is there an increased risk of stroke associated with oral contraceptives? Drug Safe. 1999; 20(6): 467 – 473.
149 Rosing J, Middeldorp S, Curvers J, Et al. Low dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study. Lancet. 1999; 354 (9195): 2036 – 2040.
150 Tyrer L. Introduction of the pill and its impact. Contraception. 1999; 59(1 Suppl): 11S – 16S.
151 Wiegratz I, Lee JH, Kutschera E, et al. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004; 70: 97 106.
152 Bagwell MA, thompson SJ, Addy Cl, et al. Primary infertility and oral contraceptives steroid use. Fertil Steril. 1995; 63 (6): 1161 – 1166.
153 Vessey MP. Benefits and risk of combined oral contraceptives. Methods. Inf Med. 1993; 32: 222 – 224.
154 Oelkers W. Drospirenone, a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J
Contracept Reprod Health Care. 2000: 5(suppl3): 17 24.
155 Godsland IF, Crook D, Devenport M, et al. Relationships between blood pressure oral contraceptive use and metabolic risk markers for cardiovascular disease. Contraception. 1995; 52: 143 149.
156 Fuchs N, Duterberg B, Weber-Diehi F. The effect on blood pressure ofa monophasic oral contraceptive containing Etinil-Estradiol andGestodene. Contraception. 1995; 51: 335 -339.
157 Arangino S, Cagnacci A, Angiolucci M. Effect of Desogestrelcontaining oral contraceptives on vascular reactivity and catecholamine levels. Contraception. 1998; 58(5): 289 – 293.
158 Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing and antimineralocorticoid progestagens, drospirenone, on the renin – aldosterone system, body weight, bloodpressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab. 1995; 80: 1816 – 1821.
159 Bracken MP. Oral contraceptive and congenital malformations in offspring. A review and meta-analysis of the prospective studies. Obstet Gynecol. 1990; 76: 552 – 562.
160 Bukvic N, Susca F, Bukvic D, et al. 17 alpha ethinyl Estradiol and Norgestrel in combination induce micronucleus increases and aneuploidy in human lymphocyte and fibroblast cultures. Teratog Carcinog Mutagen. 2000; 20(3): 147 – 159.
161 Gardyn J, Mittelman M, Zllotnik J, et al. Oral contraceptives can cause falsely low vitamin B(12) levels. Acta Haematol. 2000; 104(1): 22 – 24.
162 Yoong WC, Tuck SM, Yardumian A, et al. Red cell deformability in oral contraceptive pill users with sickle cell anaemia. Br J Haematol. 1999; 104(4): 868 – 870.
163 Apter D, Borsos A, Baumgartner W, et al. Effects of an oral contraceptive containing drospirenone and etinylestradiol on general well-being and fluid related symptoms. Eur J Contracept Reprod Health Care. 2003; 8(1): 37 51.
164 Westhoff CL Breast cancer risk: perception versus reality.Contraception. 1999; 59 (1 Suppl): 25S – 28S.
165 Hannaford PC, Combined oral contraceptives: do we know all of their effects. Contraception. 1995; 51: 325-327.
166 Collaborative Group on Hormonal Factors in breast cancer. Breast cancer and hormonal contraceptives. Lancet. 1996; 347: 1713 1727.
167 Brinton LA, Daling JR, Liff JM, et al. Contraceptives and breast cancer risk among younger women. J Natl Cancer Inst. 1995; 87: 827 835.
168 Collaborative Group on Hormonal Factors in breast cancer. Breast cancer and hormonal contraceptives further results. Contraception. 1996; 54: 1S – 10S.
169 Marchbanks PA, Mc-Donald JA, Wilson Hg, et al. Oral contraceptives and the risk of breast cancer. N Eng J Med. 2002; 346: 2025 2032.
170 Moodley J. Combined oral contraceptives and cervical cancer. Curr opinion Obstet Gynecol. 2004; 16: 27 29.
171 Viscaino AP, Moreno P, Bosch FX, et al. International trends in incidence of cervical cancer. II. Squamous cell carcinoma. Int J Cancer. 2000; 86: 429 435.
172 Ferenczy A, Eduardo F. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. 2002; 3: 11 16.
173 Meirik O. Combined oral contraceptives, human papillomavirus, and cervical cancer. IPPF Med Bull. 2002. 36: 2 -3.
174 Moodley M, Moodley J, Chetty R, et al. The role of steroid contraceptive hormones in the patogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer. 2003; 13: 103 110.
175 Briton LA, et al. Oral contraceptive use and risk of invasive cervical cancer. Int J Epidemiol. 1990; 19: 4 – 11.
176 Delgado M, Sillero M, Martin JM, et al. Contraceptives and cancer of the cervix uteri. Acta Obstet Gynecol Scand. 1992; 71: 368 – 376.
177 Brinton LA. Oral contraceptives and cervical neoplasia. Contraception. 1991; 43: 581 – 595.
178 Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives. A systematic review. Lancet. 2003; 361: 1159 1167.
179 Moreno V, Bosch FX, Muñoz N, et al. Multicentre Cervical Cancer Study Group. Effects on oral contraceptives in women with human papillomavirus. Lancet. 2002. 359: 1085 1092.
180 Holly EA, Cress RD, Ahn Dk. Cutaneous melanoma in women III. Reproductive factors and oral contraceptive use. Am J Epidemiology. 1995; 141 (10): 943 – 950.
181 Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002; 22: 201 210.
182 Chassan-Taber L, Stampfer MJ. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med. 1998; 128(6): 467 477.
183 Godsland IF, Winkler U, Lidegaard O, et al. Occlusive vascular diseases in oral contraceptive user. Epidemiology, pathology and mechanisms. Drugs. 2000; 60(4): 721 – 869.
184 Gold MA. Prescribing and managing oral contraceptive pills an emergency Contraception for adolescents. Pediatr Clin North Am. 1999; 46(4): 695 – 718.
185 Heineemann LA. Emerging evidence on oral contraceptives and arterial disease. Contraception. 2000; 62(2 Suppl): 29S – 36S.
186 Koster T, Small RA, Rosendaal Fr, et al. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Intern Med. 1995; 238: 31 37.
187 Darney PD. Combination oral contraceptives and cardiovascular disease Seminars in Reprod Endocrinol. 1996; 14(1): 51 61.
188 Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and non fatal venous Thromboembolic in women using oral contraceptives with differing progestagen components. Lancet. 1995; 346: 1589 1592.
189 Spitzer WO. Oral contraceptives and cardiovascular outcomes: cause or bias? Contraception. 2000; 622(2Suppl): 3S – 9S.
190 Word Health Organization Collaborative Study of cardiovascular disease and steroid hormone contraception. Hemorrhage stroke, overall stroke risk, and combined oral contraceptives. Results of an international multicenter case control study. Lancet. 1996; 348: 505 510.
191 Debate. What are the risks of third generation oral contraceptives? Human Reprod. 1996; 11 (4): 687 693.
192 Sidney S, Petitti DB, Soff GA, et al. Venous thromboembolic disease in users of low estrogen combined estrogen – progestin oral contraceptives. Contraception. 2004; 70: 3 10.
193 Lidegaard O. Decline in cerebral Thromboembolic among young women after introduction of low dose oral contraceptives: an incidence study for the period 1980-1993. Contraception. 1995; 52: 85 92.
194 Poulter NR, Chang Cl, Farley TM. Et al. Effect on stroke of different progestagens in low oestrogen dose oral contraceptives. WHO Collaborative Study of Cardiovascular Dissease and Steroid Hormone Contraception [Letter]. Lancett. 1999; 354(9175): 301 – 302.
195 Jick SS, Myers MW, Jick H. Risk idiopathic cerebral hemorrhage in women on oral contraceptives with differing progestagens components [Letters]. Lancet. 1999; 354(9175): 302 – 303.
196 Gillum LA, Mamidipudi SK, Johnston SC, et al. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA. 2000; 284: 72 78.
197 Petitti DB, Sidney S, Bernstein A, et al. Stroke in users of low dose oral contraceptives. N Engl J Med. 1996; 335: 8 15.
198 Rosemberg L, Palmer JR, Sands MI, et al. Modern oral contraceptives and cardiovascular disease. Am J Obstet Gynecol. 1997; 177(3): 707 – 715.

Anterior Siguiente

DÉJANOS TU COMENTARIO

DÉJANOS TU COMENTARIO

Please enter your comment!